**Question:** Which of the following is the primary neurogenic tumor?

A. Pheochromocytoma
B. Astrocytoma
C. Medulloblastoma
D. Pituitary adenoma

**Core Concept:** Neurogenic tumors are a subgroup of tumors that originate from the neuroectoderm layer during embryonic development. These tumors are classified based on their cell of origin within the nervous system.

**Why the Correct Answer is Right:** A pheochromocytoma is a tumor of the adrenal medulla, originating from chromaffin cells. Although it may secrete neurotransmitters, it is not considered a primary neurogenic tumor due to its non-neural origin.

**Why Each Wrong Option is Incorrect:**

B. Astrocytoma: A primary tumor of the central nervous system (CNS) composed of astrocytes, a type of glial cell. Although these tumors are neurogenic, astrocytoma is incorrect because it is not a primary neurogenic tumor.

C. Medulloblastoma: A primary CNS tumor originating from the embryonic neuroepithelial cells of the cerebellum. Similar to astrocytoma, medulloblastoma is neurogenic but not primary neurogenic.

D. Pituitary adenoma: A tumor arising from the pituitary gland, a neuroendocrine gland responsible for regulating hormone production. While pituitary adenomas are neurogenic tumors, they are not primary neurogenic tumors as they originate from the pituitary gland, not the nervous system.

**Clinical Pearl:** Primary neurogenic tumors are those that develop from the nervous system, while secondary neurogenic tumors arise from cells that have migrated from their original site to the affected area. Understanding the origin of these tumors is crucial for appropriate treatment strategies and patient management.

**Correct Answer:** C. Medulloblastoma

**Why Medulloblastoma is the Correct Answer:** Medulloblastoma is a primary neurogenic tumor originating from the embryonic neuroepithelial cells of the cerebellum. As it develops from neural cells within the nervous system, medulloblastoma is classified as a primary neurogenic tumor. This distinction is essential for selecting the appropriate treatment plan for patients with these tumors.